Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has issued an update.
Atomo Diagnostics has notified the ASX of a proposed issue of new securities as part of a placement or similar capital markets transaction. The company has applied for quotation of the securities in line with ASX Listing Rules, signalling compliance with regulatory processes for secondary issues.
Under the proposal, Atomo plans to issue up to 5,000,000 new broker options, exercisable at $0.045 and expiring 2.5 years from the date of issue, with an intended issue date of 7 April 2026. The options-based structure indicates an incentive mechanism for brokers and a potential future source of equity capital, which may modestly dilute existing shareholders if exercised.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. is an ASX-listed medical diagnostics company operating under the ticker AT1. The company develops and commercialises diagnostic solutions, with its securities traded on the Australian Securities Exchange under standard listing and disclosure requirements.
Average Trading Volume: 1,633,680
Technical Sentiment Signal: Buy
Current Market Cap: A$32.41M
Find detailed analytics on AT1 stock on TipRanks’ Stock Analysis page.